Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accelerate, accidental, adult, advantage, affinity, aggressively, Aldrich, alpha, analyzing, appointing, architecture, arise, arrive, assorted, award, awarded, bed, benchmark, biomanufacturing, Biopharma, blockbuster, bound, British, bundle, cease, cGMP, charter, CHMP, climate, Codification, commonly, Commonwealth, competitor, concert, conclusion, consecutive, Consortium, consummation, coordinating, correlative, council, CT, cultural, culture, currency, cylindrical, Deliverable, Denmark, denominated, dispersed, disposable, dispute, diversifying, dividing, DK, double, doubling, dramatically, efficiently, eleven, EMD, empty, endoscopy, environmental, epidermal, excise, exit, expending, facilitate, factor, fine, finite, fit, fluid, forma, fourth, Friedrich, frustrate, GAAP, GLP, goal, grown, guarantee, height, inaccurate, inadvertent, inspection, instability, insulin, iron, ISS, issuable, Italian, Italy, krona, kronor, Language, larger, leader, led, LONG®EGF, Lund, magnetic, main, managerial, media, Medicinal, merge, Millipore, month, multinational, narrow, native, network, niche, occupy, override, pain, parent, Parexel, PDUFA, pension, Perceptive, potent, pound, pressure, pro, provisional, purity, quantity, rare, reassessed, reengineered, remove, resonance, rest, rigid, rTransferrin, salary, Saracen, satisfactory, science, secondary, SecreFloTM, seller, serum, Sigma, specialist, spot, St, stem, step, sterling, Stroke, substance, supplement, supplemental, supplemented, Swedish, tagged, TC, technique, text, tomography, Topic, transferrin, translated, translation, Translational, unaudited, underway, underwent, unexercised, union, unique, unmet, User, Vag, version, water, watery, white, workforce, XBRL
Removed:
acute, advanced, aid, aiding, American, answered, attendance, bacteria, Chairman, cholangiopancreatography, communicated, complaint, counterclaimed, declaratory, deter, director, discontinuation, endoscopic, ensuring, enterprise, expedited, FASB, focused, forced, gastrinoma, GEHC, growing, guidance, hostile, immobilized, impure, invalid, invasive, judgmental, MDA, modified, monthly, past, porcine, processed, reaction, recovered, registration, retainer, retrograde, simplified, solid, successive, Trust, turn, unenforceable, unfavorably, unsuccessful, upgrade, utilized, visual, widely
Filing tables
Filing exhibits
- 10-K Annual report
- 10.18 Lease Between Repligen Sweden Ab (As Successor-in-interest to Novozymes Biopharm
- 10.19 Amendment No. 1 to Strategic Supplier Alliance Agreement
- 10.20 Strategic Supplier Alliance Agreement - Contract Manufacturing
- 10.21 Amendment to Strategic Supply Alliance Agreement
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Ernst & Young LLP
- 31.1 Rule 13A-14(A)/15D-14(A) Certification
- 31.2 Rule 13A-14(A)/15D-14(A) Certification
- 32.1 Certification Pursuant to 18 U.s.c. Section 1350, Pursuant to Section 906
Related press release
RGEN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following:
(1) | Registration Statements (Form S-8 Nos. 333-157168, 333-89140 and 33-62796) pertaining to the Second Amended and Restated 2001 Repligen Corporation Stock Plan, the 2001 Repligen Corporation Stock Option Plan, and the 1992 Repligen Corporation Stock Plan |
(2) | Registration Statements (Form S-3 Nos. 333-106109, 333-30383, 333-57951, 333-76005, 333-79611, 333-95641, 333-31728, 333-35056 and 333-36280) of Repligen Corporation |
of our reports dated March 15, 2012 with respect to the consolidated financial statements of Repligen Corporation and the effectiveness of internal control over financial reporting of Repligen Corporation, included in this Transition Report (Form 10-K) of Repligen Corporation for the nine months ended December 31, 2011.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 15, 2012